HC Wainwright Reaffirms Buy Rating for Jasper Therapeutics (NASDAQ:JSPR)

HC Wainwright reiterated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Tuesday,Benzinga reports. The firm currently has a $40.00 price objective on the stock.

Several other equities research analysts also recently commented on JSPR. Royal Bank of Canada reduced their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price for the company. Finally, UBS Group initiated coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price for the company. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $62.50.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $5.38 on Tuesday. The company has a market cap of $80.82 million, a PE ratio of -1.14 and a beta of 2.23. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01. The firm has a 50 day simple moving average of $7.04 and a 200 day simple moving average of $16.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). On average, equities analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its stake in shares of Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,873 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after purchasing an additional 3,828 shares during the last quarter. EntryPoint Capital LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $223,000. Finally, Tema Etfs LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $266,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.